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Abstract — The aim of this study was to determine the 
antibacterial and antibiofilm properties of quercetin 
against clinical isolates of Staphyloccocus aureus and 
Staphylococcus saprophyticus with resistance profile. The 
antibacterial activity of quercetin was performed by the 
determination of the minimum inhibitory concentration 
(MIC) through the microdilution method according to the 
Clinical and Laboratory Standards Institute (CLSI). The 
percentage of inhibition of Staphylococcus spp. biofilm, 
after treatment with sub-inhibitory concentrations of 
quercetin (MIC/2 and MIC/4), was evaluated by the violet 
crystal assay. Quercetin showed an antimicrobial activity 
against clinical isolates of methicillin-susceptible S. 
aureus (MSSA) (MIC = 250 µg/ml), methicillin-resistant 
S. aureus (MRSA) (MIC = 500 µg/ml), vancomycin-
intermediate S. aureus (VISA) (MIC = 125 and 150 
µg/ml), S. saprophyticus resistant to oxacillin (MIC = 
62.5 to 125 µg/ml), vancomycin-resistant S. aureus 
(VRSA) and S. saprophyticus resistant to oxacillin and 
vancomycin (MIC = 500 to 1000 µg/ml). At MIC/2 and 
MIC/4 the quercetin inhibit 46.5 ± 2.7% and 39.4 ± 4.3% 
of the S. aureus biofilm, respectively, and 51.7 ± 5.5% 
and 46.9 ± 5.5% of the S. saprophyticus biofilm, 
respectively. According to the results of this study, it was 
noticed that the quercetin presented an antibacterial 
activity against strains of Staphylococcus spp. with 
resistance profile and also inhibited the bacterial biofilm 
production even in sub-inhibitory concentrations. 
Keywords— Resistance; biofilm; quercetin; 
antibacterial activity; antibiofilm activity.  
 
I. INTRODUCTION 
Staphylococcus aureus is one of the most important 
pathogens causers of infections in humans due to its 
prevalence in hospital and community contaminations [1]. 
In general, S. aureus is associated with superficial and 
deep infections in skin and soft tissues, as well as toxin-
mediated diseases such as staphylococcal scalded skin 
syndrome, toxic shock syndrome and bacteremia with 
abscess formation that could lead, often, to the death of 
patient [1-3]. 
Resistant staphylococcal strains were observed shortly 
after the use of penicillin G in the medical clinic, in 1941. 
A few years later, in 1950, about 80% of the hospital 
samples of Staphylococcus were resistant to penicillin G, 
due to the production of penicilinases enzymes that 
inactivate this drug. Methicillin, oxacillin and its 
derivatives, as well as the first and second generation 
cephalosporins were used aiming to treat infections 
caused by Staphylococcus with resistance profile [4,5]. 
The resistance to these antimicrobials is increasing, 
mainly in hospital environments, which presents 50% of 
bacterial infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA). Another alarming factor 
is that the resistant strains of S. aureus are widely 
distributed around the world [3,6-8]. 
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Staphylococcus saprophyticus is also a species of the 
genus Staphylococcus that has a wide clinical importance. 
S. saprophyticus composes the normal microbiota of the 
skin and urinary and genitals tracts. However, when there 
is an imbalance in the microbiota, occurs the begining of 
urinary infections [2,3]. The resistance to methicillin in 
the S. saprophyticus strains has also reached a global 
distribution. Many studies defend that the main 
mechanism related to the acquisition of resistance to 
methicillin, in S. saprophyticus, is through the transfer of 
resistance genes present in the strains of MRSA or 
methicillin-resistant S. epidermidis [3,9]. 
The ability of some microorganisms to produce biofilm is 
another global public health concern. Biofilms are 
biological communities with a high degree of 
organization, in which microorganisms form structured, 
coordinated and functional communities. In addition, 
these biological communities are capable of produce 
polymeric matrices, wherein they are immersed and 
adhered to a biotic or abiotic surface [10,11]. Biofilm-
producing microorganisms are responsible for most of the 
human bacterial infections, once they have colonization 
with greater structural stability and longevity. The biofilm 
promotes a protective barrier between bacteria and the 
environment, acting like an important virulence and 
pathogenicity factor, making these bacteria highly 
resistant to antimicrobials and host immunity [11,12]. In 
this way, it is important to conduct studies to identify the 
bacterial resistance phenotype, in order to contribute to 
epidemiological surveillance, especially of the genus 
Staphyloccocus, one of leading causes of nosocomial 
infections. 
The dissemination, especially in hospital environments, of 
these pathogens resistant to antimicrobial agents and 
biofilm producers, represents a serious threat to public 
health, implying in the therapeutic failure of many 
infectious diseases [13,14]. Despite of the development of 
new antimicrobials by pharmaceutical industry in the last 
three decades, infections caused by bacteria of genus  
Staphylococcus are still an alarming health problem. 
Therefore, it is necessary to discover new therapeutic 
options with antimicrobial and antibiofilm activity [13-
16]. 
The flavonoids, secondary metabolites of the polyphenols 
class, are found in vegetables, fruits, nuts, honey, s tems 
and flowers. Quercetin, 3,5,7,3'-4'-pentahydroxy flavone, 
is the most abundant flavonoid present in the human diet 
and represents about 95% of the total ingested flavonoids. 
This molecule is one of the most studied flavonoids due 
to its biological activities, such as antiviral, antimicrobial, 
antioxidant, antithrombotic and antitumoral. Some studies 
have described its antimicrobial activity against some 
microorganisms, such as Bacillus subtilis, Micrococcus 
luteus and Aspergillus flavus [17,18]. Despite of the 
existence of studies that already report its antimicrobial 
activity, there are no researches regarding its 
antimicrobial and antibiofilm activity against clinical 
isolates of Staphylococcus spp. resistant to vancomycin.  
In this way, the aim of this study was to evaluate the 
antimicrobial and antibiofilm activities of quercetin 
against Staphylococcus spp. clinical isolates with 
resistance profile. 
 
II. MATERIAL AND METHODS 
2.1 Identification of clinic isolates 
Staphylococcus spp. clinical isolates were provided by a 
university hospital of Pernambuco, in the period from 
January to March 2017. The isolates were seeded in 
nutrient Agar (AN) for subsequent identification of 
bacteria. After that, the samples were seeded in Baird 
Parker Agar (BPA) base supplemented with 2% Egg yolk 
Tellurite emulsion (Hi-Media), incubated at 35 ± 2 °C for 
48 h. The typical colonies of S. aureus (shiny black with 
an opaque ring, surrounded by a clear halo) were 
submitted to gram stain, catalase assay, coagulase, 
mannitol salt Agar assay and DNAse for Staphylococcus 
aureus identification. The colonies that did not presented 
typical aspects were submitted to gram stain, catalase 
assay and novobiocin sensitivity tests (5 µg), to identify S. 
saprophyticus (resistant to novobiocin) or S. epidermidis 
(sensitive to novobiocin) [19,20]. Methicillin-sensitive 
Staphylococcus aureus (MSSA) ATCC 29213 and MRSA 
ATCC 33591 were used as control strains. 
2.2 Identification of resistance profile of the clinical 
isolates 
The identification of resistance profile of the 
Staphylococcus spp. clinical isolates was conducted 
according to Clinical and Laboratory Standards Institute 
[21]. For the identification of MRSA, vancomycin-
intermediate Staphylococcus aureus (VISA), 
vancomycin-resistant Staphylococcus aureus (VRSA) and 
S. saprophyticus resistant to cefoxitin, oxacillin and 
vancomycin were submitted to the method of disk 
diffusion with cefoxitin, oxacillin and vancomycin; 
microdilution method with oxacillin and vancomycin; as 
well as screening for oxacillin and vancomycin [21].  
For the disk diffusion method, inocula of microorganisms 
were adjusted to 0.5 of the McFarland scale and seeded in 
Müeller Hinton Agar (MHA). Then, cefoxitin, oxacillin 
and vancomycin were deposited on the plates and 
incubated at 35 ± 2 °C for 24 h. After incubation, the 
inhibition halos were measured and analyzed following 
the CLSI cutting points [21]. 
The minimum inhibitory concentration (MIC) was 
determined by the microdilution method according to the 
CLSI [21]. Initially, 95 µl of Müeller Hinton Broth 
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(MHB) was added to all plate wells. After, oxacillin and 
vancomycin were added in concentrations range from 0.5 
to 256 µg/ml or 0.0625 to 32 µg/ml, respectively. 
Bacterial suspensions were adjusted to 0.5 of the 
McFarland scale, diluted and added in the wells  to obtain 
a final concentration of 2–5 x 105 CFU/well. 
Subsequently, the plates were incubated at 35 ± 2 °C for 
24 h. The MIC was determined as the lowest 
concentration of the standard drug able to inhibit >90% of 
the microbial growth through spectrophotometry at 620 
nm. 
The minimum bactericidal concentration (MBC) was 
determined after the obtained results of MIC. An aliquot 
of the wells with no microbial growth was inoculated in 
MHA and the plates were incubated at 35 ± 2 °C by 20-24 
h. After this period, the MBC was determined as the 
lowest concentration with no microbial growth. The 
samples were analyzed following the CLSI cutting points 
[21].  
In the screening test, initially, plates with Müeller Hinton 
Agar containing 4% NaCl and 6 µg/ml of oxacillin and 
plates with Brain Heart Infusion Agar (BHIA) containing 
4% NaCl and 6 µg/ml of vancomycin were prepared. 
Then, microorganism inocula were adjusted to 0.5 of the 
McFarland scale and seeded in the plates. Finally, the 
plates were incubated at 35 ± 2 °C for 24 h. The plates 
were carefully observed against the light and any growth 
after 24 h was considered resistant to oxacillin and/or 
vancomycin [21]. 
2.3 Phenotypic characterization of biofilm production 
2.3.1 Congo Red Agar test 
The qualitative determination of biofilm production by 
clinical isolates was carried out according to the method 
of Congo Red Agar [22]. The isolates were adjusted to 0.5 
of the McFarland scale (108 CFU/ml) in BHIA, incubated 
at 35 ± 2 ºC for 24 h and seeded in plates containing 
Congo Red Agar. Subsequently, they were incubated in 
aerobic environment at 35 ± 2 ºC for 48 h. After this 
period, the colonies with blackened coloration, with dry 
or rough consistency, were considered as biofilm-
producers. Colonies of red color, with mucous 
consistency, were considered as not biofilm-producers. 
The experiment was performed in triplicate and in 3 
different days. 
2.3.2 Violet crystal staining 
The quantitative determination of biofilm production was 
performed by the method of violet crystal staining [23]. 
Initially, the bacterial isolates were seeded in AN and 
incubated at 35 ± 2 °C for 18-24 h. Inocula were 
incubated in Tryptone Soy Broth (TSB) with 1% glucose 
for 24 h. Every culture was adjusted to 0.5 of the 
McFarland scale (108 CFU/ml) in the TSB with 1% 
glucose and the adjusted bacterial suspension was added 
to 96 wells plate with flat bottom. The plates were 
incubated at 35 ± 2 °C for 48 h. Then, the wells content 
were aspirates and washed with phosphate buffer (pH 
7.4). Next, 200 µl of 99% methanol was added and 
incubated. After 15 minutes of incubation, the content 
was discarded. Subsequently, a solution of 1% of violet 
crystal stain was added in the wells and the plates were 
kept at room temperature for 30 minutes. The wells 
content was removed and washed with phosphate buffer. 
A solution of 33% glacial acetic acid was added and the 
optical density (OD) was measured by spectrophotometry 
at 570 nm (Multiskan microplate photometer FC, Thermo 
scientific, Madrid, Spain). Wells containing only the 
culture medium were used as control.  The strains were 
classified into four categories, based on the values of ODs 
of bacterial biofilms, in comparison with value of the 
ODc (optical density of the control). The strains were 
classified into non-adherent if OD ≤ ODc; weak biofilm 
producer if ODc < OD ≤ 2 × ODc; moderate biofilm 
producer if 2 × OD ≤ 4 × ODc < ODc; or strong biofilm 
producer if 4 × ODc < OD [23]. The experiment was 
performed in triplicate and in 3 different days. 
2.4 Antimicrobial activity of quercetin 
The antimicrobial activity of quercetin (Sigma-Aldrich®) 
was performed by the microdilution method, already 
described previously, according to the CLSI [21]. The 
range of concentration of quercetin used in this study was 
2 to 1000 µg/ml. The experiment was performed in 
triplicate and in 3 different days. 
2.5 Biofilm formation-inhibition test  
The antibiofilm activity of quercetin was carried out 
according to Das, Yang and Ma [24]. Initially, inocula 
were adjusted to 0.5 of the McFarland scale (108 CFU/ml) 
in TSB with 1% glucose and diluted to obtain bacterial 
cells concentration of 105 CFU/ml.  These inocula 
weredistributed in 96 plate flat-bottom wells and 
incubated at 37 ± 2 °C for 24 h. Later, the wells content 
was removed and quercetin was added in MIC, MIC/2 
and MIC/4. The plates were incubated at 35 ± 2 °C for 24 
h. Then, the wells content was aspirated and the violet 
crystal stain method was performed, as described in 
section 2.3.2. The experiment was performed in triplicate 
and in 3 different days. 
 
III. RESULTS AND DISCUSSION 
3.1 Identification of species and phenotypic resistance 
profile 
The identification of microorganism’s  prevalence in a 
given region is essential for the implementation of 
containment measures of infections caused by these 
bacteria. In addition to the knowledge of the species that 
cause infection, the identification of the resistance profile 
is of great importance for infections treatment caused by 
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these microorganisms [14]. The prevalence of resistant 
bacteria of genus  Staphylococcus in hospital and 
community infections, especially in immunosuppressed 
individuals, makes these bacteria important subjects in 
research studies [3,6]. 
Bacteria of the genus Staphylococcus are recognized for 
their ability to develop drug resistance, prolonging the 
patient's treatment time and causing high morbidity and 
mortality rates [3-6]. One of the main bacterial resistance 
profiles of the genus Staphylococcus is the resistance to 
oxacillin [5.6], which was identified in most S. aureus 
strains and in all S. saprophyticus strains of the present 
study.  
Sina et al. [25] analyzed 1904 urogenital samples and 
isolated, about, 80 strains of Staphylococcus spp.. 
Staphylococcus aureus was identified in 30% of the 
samples and 70% as species of coagulase-negative 
Staphylococcus. Among these 70%, 50% were identified 
as S. saprophyticus. The proportion of resistance to 
methicillin was 54.17% for S. aureus and 52.50% for S. 
saprophyticus. 
Vancomycin, an antimicrobial of the glycopeptide class, 
is, practically, the only option of treatment for infections 
caused by methicillin-resistant Staphylococcus strains. 
Although, vancomycin is currently demonstrating 
inefficiency in some cases [26,27]. The arising of clinical 
isolates with intermediate resistance or resistant to 
vancomycin is one of the reasons that worries the 
worldwide organizations related to public health, as well 
as an alert to health professionals [27]. 
Studies indicate that the appearance of the antibiotic 
resistance phenotypes of VISA is related to 
hospitalization and persistent infection [26,27], and may 
arise when a single colony of bacterial cells, formed 
mostly by cells that do not have resistance to vancomycin 
(MIC ≤ 2 µg/ml), has an antibiotic-resistant 
subpopulation at intermediate level (MIC = 4 to 8 µg/ml) 
[26]. The first cases of vancomycin resistance were only 
described in the year of 2000, in Rio de Janeiro and 2002 
in Japan [28]. 
Almeida et al. [28] analyzed S. aureus clinical isolates 
from infections in patients of a university hospital in the 
city of Londrina, from 2001 to 2004, where 70% of the 
strains were resistant to oxacillin and none of them 
showed resistance to vancomycin. Moreira et al. [29] 
performed phenotypic tests  in samples of Staphylococcus 
aureus from patients and members of the nursing team of 
a tertiary hospital to verify their resistance profile to 
oxacillin and vancomycin. In their study, 75% of the 
strains were MRSA and all were sensitive to vancomycin.   
Tiwari and Sen [30] conducted an epidemiological study 
that estimated the presence of vancomycin resistance in 
samples of patients with S. aureus and coagulase-negative 
Staphylococcus, from a hospital in northern India. The 
group analyzed 783 strains of S. aureus, where 10 of them 
showed resistance to glycopeptides, 8 of these strains 
were resistant to vancomycin. Although this study was 
performed 11 years ago, the increasing incidence of 
Staphylococcus spp. with a resistance profile turns evident 
the worrying in the recent years, bringing the reflection 
that the resistance phenotype VRSA can be as frequent as 
the phenotype MRSA in the present day. 
Hannan et al. [31] evaluated the resistance profile of 240 
clinical isolates of S. aureus, obtained from 4 tertiary 
hospitals in Pakistan from July to December 2014.  The 
study showed that 215 (89%) of the S. aureus strains were 
sensitive to vancomycin, at concentrations ranging from 
1.0 to 2.0 µg/ml, while 25 (11%) of the strains exhibited 
MIC > 2 µg/ml. 
 
Table.1: Identification of the resistance phenotypic profile of Staphylococcus aureus clinical isolates. 
Sample identification Inhibition halos 
(mm) 
MIC 
(µg/ml) 
Screening Resistance 
profile 
OXA CFO VAN OXA VAN OXA VAN 
 
MSSA ATCC 29213 
 
20.2 ± 1.7 
 
29.5 ± 1.3 
 
18.2 ± 0.6 
 
1 
 
2 
 
- 
 
- 
 
MSSA 
LMB 150 18.8 ± 1.1 21.4 ± 1.2 17.7 ± 1.2 1 2 - - MSSA 
LMB 151 16.2 ± 0.9 17.2 ± 1.1 21.1 ±1.6 1 1 - - MSSA 
LMB 152 20.2 ± 2.1 30.2 ± 1.6 21.3 ± 0.5 2 1 - - MSSA 
MRSA ATCC 33591 0 12.5 ± 1.2 25.2 ± 0.6 > 256 1 + - MRSA 
LMB 153 0 14.3 ± 1.7 22.4 ± 1.3 8 2 + - MRSA 
LMB 154 0 11.1 ± 0.6 23.6 ± 1.7 > 256 2 + - MRSA 
LMB 155 0 17.7 ± 1.5 11.4 ± 0.2 16 8 + - VISA 
LMB 156 0 19.3 ± 0.6 11.8 ± 0.6 16 4 + - VISA 
LMB 157 0 18.6 ± 0.6 10.4 ± 0.2 > 256 16 + + VRSA 
LMB 158 0 20.1 ± 0.8 0 > 256 > 32 + + VRSA 
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MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; VISA: 
vancomycin-intermediate S. aureus; VRSA: vancomycin-resistant Staphylococcus aureus; ATCC: American Type Culture 
Collection; MIC: Minimum Inhibitory Concentration; LMB: Laboratory of Microbiology; OXA: Oxacillin; VAN: 
Vancomycin.  
Table.2: Identification of the resistance phenotypic profile of Staphylococcus saprophyticus clinical isolates. 
MIC: Minimum Inhibitory Concentration; LMB: Laboratory of Microbiology; OXA: Oxacillin; VAN: Vancomycin; CFO: 
Cefoxitin. 
 
3.2 Phenotypic characterization of biofilm production 
In the Congo Red Agar test, all 22 Staphylococcus clinical 
isolates were characterized as biofilm-producers (fig. 1). 
In the violet crystal method, all strains were characterized 
as biofilm-producers, being 1 classified as a low producer 
(4.5%), 10 as strongly biofilm-producer (45.5%) and 11 
as moderately biofilm-producer (50%) (Table 3). This 
compatibility in the results for quantitative and qualitative 
methods that evaluated the biofilm production by bacteria 
of the genus  Staphylococcus has been described in other 
studies [32,33]. 
  
 
Fig.1: Evaluation of biofilm production by Congo Red 
Agar test. 
LMB 159 0 0 0 > 256 > 32 + + VRSA 
LMB 160 0 18.2 ± 1.2 0 > 256 > 32 + + VRSA 
LMB 161 0 0 8.1 ± 0.5 > 256 > 32 + + VRSA 
LMB 162 0 16.4 ± 2.1 7.2 ± 0.8 > 256 > 32 + + VRSA 
Sample 
identification 
Inhibition halos 
(mm) 
MIC 
(µg/ml) 
Screening 
Resistance profile 
 OXA CFO VAN OXA VAN OXA VAN 
LMB 163 17.3 ± 1.5 24.0 ± 2.3 8 > 256 2 + - S. saprophyticus resistant to 
OXA and CFO 
LMB 164 0 21.0 ± 1.4 0 > 256 4 + - S. saprophyticus  resistant to 
OXA and CFO 
LMB 165 0 21.0 ± 1.3 0 32 2 + - S. saprophyticus  resistant to 
OXA and CFO 
LMB 166 8.2 ± 0.9 12.1 ± 0.7 2 > 256 > 32 + + S. saprophyticus resistant to 
OXA, CFO and VAN 
LMB 167 0 17.4 ± 2.1 0 > 256 > 32 + + S. saprophyticus resistant to 
OXA, CFO and VAN 
LMB 168 0 18.3 ± 1.1 0 > 256 > 32 + + S. saprophyticus  resistant to 
OXA, CFO and VAN 
LMB 169 0 12.8 ± 0.7 0 > 256 > 32 + + S. saprophyticus  resistant to 
OXA, CFO and VAN 
LMB 170 0 10.1 ± 0.2 0 > 256 > 32 + + S. saprophyticus  resistant to 
OXA, CFO and VAN 
LMB 171 0 0 0 > 256 16 + + S. saprophyticus  resistant to 
OXA, CFO and VAN 
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MSSA: Methicillin-sensitive Staphylococcus aureus; 
MRSA: Methicillin-resistant Staphylococcus aureus; 
LMB: Laboratory of Microbiology. 
According to the national health institutes publications, 
microorganisms that produce biofilm are related to more 
than 65-80% of the bacterial infections [32-35]. Hassan et 
al. [32] evaluated the ability of biofilm production in 110 
clinical isolates of pathogenic bacteria, of different 
species, by the method of violet crystal staining. The 
obtained results were similar to our results that showed 
production of biofilm in all strains (100%), of which, 
22.7% were classified as strongly producers, 41% 
moderate producers and 36.3% were weak producers. 
Shrestha et al. [33] noticed the biofilm production in 82% 
of 71 clinical isolates of the genus  Staphylococcus. 
3.3 Antibacterial and antibiofilm activities of 
quercetin 
In the evaluation of antimicrobial activity of quercetin 
against S. aureus and S. saprophyticus, with different 
resistance profiles, it’s observed that this molecule has a 
bacteriostatic effect against all microorganisms tested. 
Quercetin exhibit MIC values ranged from 250 to 1000 
µg/ml for Staphylococcus aureus (Table 4) and 62.5 to 
1000 µg/ml for Staphylococcus saprophyticus (Table 5). 
In addition, the molecule was able to inhibit the biofilm 
production by these bacteria, even when analyzed in sub-
inhibitory concentrations (Tables 4 and 5). 
Quercetin showed MIC of 250 µg/ml, 500 µg/ml and 125 
to 250 µg/ml against MSSA, MRSA and VISA, 
respectively. The best inhibitory activity of quercetin  was 
against the S. saprophyticus strains resistant to oxacillin 
and cefoxitin (MIC = 62.5 to 125 µg/ml). The lower 
inhibitory activity of quercetin was observed against the 
VRSA strains and S. saprophyticus resistant to 
vancomycin, oxacillin and cefoxitin (MIC = 500 to 1000 
µg/ml).  
To show a good antibacterial activity, the molecule has to 
present MIC < 100 µg/ml, moderate activity with MIC 
between 101 and 500 µg/ml, weakly active when MIC is 
between 501 and 1000 µg/ml, and is inactive when MIC > 
1001 µg/ml [36]. So, quercetin, in general, presented 
moderate antibacterial activity against the clinical isolates 
tested, except for VRSA and S. saprophyticus resistant to 
vancomycin, oxacillin and cefoxitin, where this molecule 
showed a weak activity. 
Studies evaluated the antimicrobial activity of quercetin 
against bacterial strains using the disk diffusion or Agar 
diffusion method. Rauha et al. [37] observed that 
quercetin presented antimicrobial activity at concentration 
of 500 µg/ml against ATCC strains of the species: 
Aspergillus niger, Bacillus subtilis, Candida albicans, 
Escherichia coli, Micrococcus luteus, Pseudomonas 
aeruginosa, Saccharomyces cerevisiae, Staphylococcus 
aureus and Staphylococcus epidermidis, determined by 
the disc diffusion method. Gatto et al. [17] found no 
antibacterial activity of this flavonoid, in the 
concentration of 100 µg/ml, in any of the tested bacteria 
(Staphylococcus aureus, Bacillus subtilis, Listeria 
ivanovi, Listeria monocytogenes, Listeria serligeri, 
Escherichia coli, Shigella flexneri, Shigella sonnei, 
Salmonella enteritidis and Salmonella tiphymurium).  
Nitiema et al. [38] evaluated the antibacterial activity of 
quercetin, at a concentration of 1000 µg, through Agar 
diffusion method, and did not observe any activity of this 
molecule against bacterial strains causers of 
gastroenteritis. Studies that use qualitative and less 
precise methods, such as disk diffusion and Agar 
diffusion, are able to identify the antibacterial activity of 
quercetin, but they cannot determine the minimum 
inhibitory concentration. Thus, quantitative methods are 
important for a future in vivo drugs application, because 
they help in the determination of the dose that will be 
used in the treatment of infection, in humans and animals 
[16]. 
Table.3: Biofilm production from clinical isolates of the genus Staphyloccocus. 
Sample identification Bacteria identification Congo Red Agar test Violet crystal staining 
assay 
MSSA ATCC 29213 S. aureus + Strong 
LMB 150 S. aureus + Strong 
LMB 151 S. aureus + Strong 
LMB 152 S. aureus + Strong 
MRSA ATCC 33591 S. aureus + Moderate 
LMB 153 S. aureus + Strong 
LMB 154 S. aureus + Weak 
LMB 155 S. aureus + Moderate 
LMB 156 S. aureus + Moderate 
LMB 157 S. aureus + Strong 
LMB 158 S. aureus + Moderate 
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MSSA: Methicillin-sensitive Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus; ATCC: American 
Type Culture Collection; LMB: Laboratory of Microbiology; (+): production of biofilm.
  
Table.4: Antibacterial and antibiofilm activities of quercetin against Staphylococcus aureus clinical isolates. 
MSSA: Methicillin-sensitive Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus; VISA: 
Vancomycin-intermediate Staphylococcus aureus; VRSA Vancomycin-resistant Staphylococcus aureus; ATCC: American 
Type Culture Collection; LMB: Laboratory of Microbiology; MIC: Minimum Inhibitory Concentration; QUER: Quercetin.
LMB 159 S. aureus + Moderate 
LMB 160 S. aureus + Moderate 
LMB 161 S. aureus + Strong 
LMB 162 S. aureus + Strong 
LMB 163 S. saprophyticus + Moderate 
LMB 164 S. saprophyticus + Moderate 
LMB 165 S. saprophyticus + Moderate 
LMB 166 S. saprophyticus + Strong 
LMB 167 S. saprophyticus + Strong 
LMB 168 S. saprophyticus + Strong 
LMB 169 S. saprophyticus + Moderate 
LMB 170 S. saprophyticus + Moderate 
LMB 171 S. saprophyticus + Moderate 
Sample identification Resistance 
profile 
Biofilm 
productio
n 
MIC of QUER 
(µg/ml) 
% of biofilm inhibition 
  
MIC MIC/2 MIC/4 
MSSA ATCC 29213 MSSA  Strong 250 49.4 ± 1.2 43.4 ± 3.1 34.6 ± 1.4 
LMB 150 MSSA Strong 250 47.3 ± 0.9  44.7 ± 0.8 36.3 ± 3.9 
LMB 151 MSSA Strong 250 49.4 ± 2.1 44.1 ± 2.3 33.1 ± 2.0 
LMB 152 MSSA Strong 250 48.4 ± 1.7 45.4 ± 2.2 37.8 ± 1.4 
MRSA ATCC 33591 MRSA Moderate 500 52.8 ± 0.6 49.7 ± 1.4 42.2 ± 0.9 
LMB 153 MRSA Strong 500 48.4 ± 1.5 43.9 ± 3.9 35.5 ± 0.5 
LMB 154 MRSA Weak 500 58.3 ± 1.4 52.4 ± 1.5 46.1 ± 1.6 
LMB 155 VISA Moderate 250 55.3 ± 2.4 48.9 ± 0.6 41.5 ± 1.3 
LMB 156 VISA Moderate 125 54.6 ± 2.0 48.6 ± 0.8 44.5 ± 2.3 
LMB 157 VRSA Strong 1000 47.1 ± 1.7 44.7 ± 1.7 36.6 ± 0.9 
LMB 158 VRSA Moderate 500 57.2 ± 1.8 47.4 ± 2.2 43.7 ± 1.1 
LMB 159 VRSA Moderate 500 55.5 ± 0.8 46.6 ± 2.4 43.9 ± 1.8 
LMB 160 VRSA Moderate 500 58.5 ± 2.9 49.5 ± 0.5 44.5 ± 0.8 
LMB 161 VRSA Strong 1000 46.7 ± 0.9 44.7 ± 0.6 36.4 ± 1.7 
LMB 162 VRSA Strong 1000 47.7 ± 1.4 43.8 ± 1.7 35.2 ± 3.1 
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Table.5: Antibacterial and antibiofilm activities of quercetin against S. saprophyticus clinical isolates. 
LMB: Laboratory of Microbiology; MIC: Minimum Inhibitory Concentration; QUER: Quercetin; OXA: Oxacillin; VAN: 
Vancomycin; CFO: Cefoxitin. 
Additionally, researches show the potential of quercetin 
combined to other drugs for bacterial infections treatment 
caused by Staphylococcus spp.. Hirai et al. [39] analyzed 
the activity of quercetin in combination with other 
antimicrobials against MRSA strains. Quercetin, in the 
concentration of 50 µg/ml, enhanced in vitro antibacterial 
activity of ampicillin (0.5 µg/ml), erythromycin (8 
µg/ml), gentamicin (0.5 µg/ml), oxacillin (0.8 µg/ml) and 
vancomycin (0.125 µg/ml).  
Regarding the quercetin antibiofilm activity, this 
molecule reduces the bacterial biofilm of S. aureus at 
MIC, MIC/2 and MIC/4, when compared to the negative 
control (p < 0.05). Quercetin, at MIC, reduced 53.2 ± 
5.0%, 59.7 ± 5.5%, 51.6 ± 0.4% and 56.5 ± 5.8% against 
MRSA and VRSA, S. saprophyticus resistant to OXA and 
CFO and S. saprophyticus resistant to OXA, CFO and 
VAN, respectively. At MIC/2, quercetin reduced 48.67 ± 
0.61%, 45.7 ± 2.0%, 54.5 ± 1.1% and 50.5 ± 5.9% the 
bacterial biofilm of MRSA, VRSA, S. saprophyticus 
resistant to OXÅ and CFO; and S. saprophyticus resistant 
to OXA, CFO and VAN, respectively. At MIC/4, 
quercetin reduced 42.2 ± 5.3%, 40.2 ± 4.4%, 45.9 ± 0.8% 
and 48.4 ± 6.7% the bacterial biofilm of MRSA, VRSA, 
S. saprophyticus resistant to OXA and CFO, and S. 
saprophyticus resistant to OXA, CFO and VAN, 
respectively. Lee et al. [40] evaluated the ability of 
quercetin to inhibit the formation of biofilm of S. aureus 
ATCC 6538, through the method of violet crystal staining 
and verified 80% of inhibition on bacterial biofilm in the 
concentration at 50 µg/ml.   
The relevance of our results in the evaluation of the 
antibiofilm activity of quercetin was to prove that this 
molecule, even in sub-inhibitory concentrations, is able to 
inhibit the formation of biofilm. This is an important fact, 
because some commercial drugs, such as macrolides 
acetilisovaleriltilosin tartrate and erythromycin, when 
used at lower concentrations than the values of MIC, 
stimulates the formation of biofilm in Staphylococcus 
strains, inducing resistance in clinical isolates of the 
genus  Staphylococcus [6,41]. 
 
IV. CONCLUSION 
In this study, we showed that the S. aureus is the major 
cause of bacterial infection in genus Staphylococcus, 
followed by a high incidence of S. saprophyticus. In 
addition, there is a concern on the incidence of resistant 
bacterial strains among patients of this hospital in 
Pernambuco, evidenced by the occurrence of 
vancomycin-resistant strains and the high incidence of 
strains that are strongly biofilm producers. In this way, we 
emphasize the need for identification of the resistance 
profile of clinical isolates, as well as the ability of this 
isolates to produce biofilm, once that these two factors are 
important to bacteria survival and could explain the 
inefficiency of many treatments.  According to our results 
of antimicrobial and antibiofilm activities  of quercetin, we 
can affirm that this molecule exhibited a promising 
Sample 
identification 
Resistance profile Biofilm 
production 
MIC of 
QUER 
(µg/ml) 
% biofilm inhibition 
 MIC MIC/2 MIC/4 
LMB 163 S. saprophyticus resistant to OXA 
and CFO 
Moderate 62.5 60.2 ± 1.4 55.5 ± 1.8 49.1 ± 1.2 
LMB 164 S. saprophyticus resistant to OXA 
and CFO 
Moderate 125 59.6 ± 0.9 54.8 ± 0.6 48.4 ± 1.3 
LMB 165 S. saprophyticus resistant to OXA 
and CFO 
Moderate 125 59.7 ± 1.7 53.2 ± 0.8 47.9 ± 2.1  
LMB 166 S. saprophyticus is resistant to 
OXA, CFO and VAN 
Strong 500 50.4 ± 0.6 43.8 ± 1.2 39.2 ± 1.5 
LMB 167 S. saprophyticus resistant to OXA, 
CFO and VAN 
Strong 500 52.3 ± 2.4 45.1 ± 1.3 40.3 ± 0.8 
LMB 168 S. saprophyticus resistant to OXA, 
CFO and VAN 
Strong 1000 50.9 ± 1.4 44.6 ± 0.9 40.6 ± 1.1 
LMB 169 S. saprophyticus resistant to OXA, 
CFO and VAN 
Moderate 500 62.8 ± 0.7 56.4 ± 0.9 52.2 ± 2.3 
LMB 170 S. saprophyticus resistant to OXA, 
CFO and VAN 
Moderate 1000 60.7 ± 3.1 56.4 ± 1.1 51.1 ± 0.5 
LMB 171 S. saprophyticus resistant to OXA, 
CFO and VAN 
Moderate 1000 61.5 ± 0.8 55.9 ± 2.4 53.4 ± 1.3 
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antibacterial activity against VISA and S. saprophyticus 
strains resistant to OXA and CFO and weak activity 
against VRSA strains and S. saprophyticus resistant to 
OXA, CFO and VAN. Regards the antibiofilm activity, 
even at sub-inhibitory concentrations, quercetin inhibited, 
approximately, 50% of the biofilm produced by isolates 
of S. aureus and S. saprophyticus vancomycin-resistant 
and, in consequence, reduced the resistance that could be 
caused by the increase in bacterial biofilm formation. 
Finally, further studies must be conducted in order to 
analyze the in vivo antibacterial activity of quercetin in 
infections caused by Staphylococcus species. 
 
ACKNOWLEDGEMENTS  
SD Costa-Junior thanks the National Council for 
Scientific and Technological Development (CNPq) for 
MSc scholarship. This study was funded by Foundation of 
Support for Science and Technology of the State of 
Pernambuco (FACEPE) [APQ-0814-4.03/17]. 
 
REFERENCES 
[1] Kane, T. L.; Carothers, K. E.; Lee, A. W. (2018). 
Virulence factor targeting of the bacterial pathogen 
Staphylococcus aureus for vaccine and therapeutics. 
Current Drug Target, v. 19, n. 2, p. 111-127.  
[2] Zurita, J.; Mejía, C.; Guzmán-Blanco, M. (2010). 
Diagnosis and susceptibility testing of methicillin-
resistant Staphylococcus aureus in Latin America. 
The Brazilian Journal of Infectious Diseases. v. 14, 
n. 2, p. 97-106. 
[3] McCarthy, H.; Rudkin, J. K.; Black, N. S.; 
Gallagher, L.; O’Neill, E.; O’Gara, J. P. (2015). 
Methicillin resistance and the biofilm phenotype in 
Staphylococcus aureus. Frontiers in Cellular and 
Infection Microbiology. v. 5, p.1-9. 
[4] Tavares, W. (2000). Bactérias gram-positivas 
problemas: resistência de estafilococos, do 
enterococos, e do pneumococo aos antimicrobianos. 
Revista da Sociedade Brasileira de Medicina 
Tropical. v. 33, n. 3, p. 281-30. 
[5] Pantosti, A. (2012). Methicillin-resistant 
Staphylococcus aureus associated with animals and 
its relevance to human health. Frontiers 
Microbiology. v. 3, n. 127, p. 1-12. 
[6] Wang, Q.; Sun, F. J.; Liu, Y.; Xiong, L. R.; Xie, L. 
L.; Xia, P. Y. (2010). Enhancement of bioﬁlm 
formation by subinhibitory concentrations of 
macrolides in icaADBC-positive and -negative 
clinical isolates of Staphylococcus epidermidis. 
Antimicrobial Agents and Chemotherapy. v. 54, n. 6, 
p. 2707-2711. 
[7] Adams, R.; Smith, J.; Locke, S.; Phillips, E.; Erol, 
E.; Carter, C.; Odoi, A. (2018). An epidemiologic 
study of antimicrobial resistance of Staphylococcus 
species isolated from equine samples submitted to a 
diagnostic laboratory. BMC Veterinary Research, v. 
14, n. 1, p. 1-12.  
[8] Dehkordi, F. S.; Gandomi, H.; Basti, A. A.; Misaghi, 
A.; Rahimi, E. (2017). Phenotypic and genotypic 
characterization of antibiotic resistance of 
methicillin resistant Staphylococcus aureus isolated 
from hospital food. Antimicrobial Resistance and 
Infection Control, v. 2018, n. 1, p. 1-11.  
[9] Toribio, M. S.; Fernández, J. G. (2013). 
Staphylococcus aureus resistente à meticilina: una 
emergencia sanitaria en medicina humana y una 
alerta para la ciencia veterinaria. Revista Ciencias 
Veterinarias. v. 15, n. 1, p. 83–96. 
[10] Le, K. Y. (2014). Molecular determinants of 
staphylococcal biofilm dispersal and structuring. 
Frontiers in Cellular and Infection Microbiology . v. 
2, n. 167, p. 1-7. 
[11] Gabrilska, R. A.; Rumbaugh, K. P. (2015). Biofilm 
models of polymicrobial infection. Future 
Microbiology. v. 10, n. 12, p. 1997-2015, 
[12] Acker, V. H.; Dijick, P. V.; Coenye, T. (2014). 
Molecular mechanisms of antimicrobial tolerance 
and resistance in bacterial and fungal biofilms. 
Trends in Microbiology. v. 22, n. 6, p. 326-333. 
[13] Linardi, V. R.; Coelho-Neto, M. N.; Araujo, P. L.; 
Silva, E. F. (2014). Isolamento de Staphylococcus 
aureus MRSA entre os funcionários de um hospital 
geral da região leste de Minas Gerais. Revista de 
Saúde Pública do SUS, v. 2, n. 2, p. 59-64. 
[14] Correa, M. E.; França, A. A.; Castro, A. A.; 
Fernandes, E. T.; Ferreira, I. M.; Silva, L. F. et al. 
(2017). Mechanism of aggression and defense and 
its correlation with the hospital infection control 
commission. Revista Científica Fagoc Saúde, v. 2, n. 
1, p. 1-6. 
[15] Nascimento, G. G. F.; Locatelli, J.; Freitas, P. C.; 
Silva, G. L. (2000). Antibacterial activity of plant 
extracts and phytochemicals on antibiotic-resistant 
bacteria. Brazilian Journal of Microbiolog , v. 31, n. 
4, p. 247-256. 
[16] Elisha, I. L.; Botha, F. S.; McGaw, L. J.; Eloff, J. N. 
(2017). The antibacterial activity of extracts of nine 
plant species with good activity against Escherichia 
coli against five other bacteria and cytotoxicity of 
extracts. BMC Complementary and Alternative 
Medicine, v. 17, n. 1, p. 133-143. 
[17] Gatto, M. T.; Falcocchio, S.; Grippa, E.; Mazzanti, 
G.; Battinelli, L.; Nicolosi, G. et al. (2002). 
Antimicrobial and anti-lipase activity of quercetin 
and its C2-C16 3-O-acyl-esters. Bioorganic & 
Medicinal Chemistry, v. 10, n. 2, p. 269-272. 
 International Journal of Environment, Agriculture and Biotechnology (IJEAB)                             Vol-3, Issue-5, Sept-Oct- 2018 
http://dx.doi.org/10.22161/ijeab/3.5.50                                                                                                                      ISSN: 2456-1878 
www.ijeab.com                                                                                                                                                                           Page | 1957  
[18] Gopikrishnan, V.; Radhakrishnan, M.; 
Pazhanimurugan, R.; Shanmugasundaram, T.; 
Balagurunathan, R. (2017). Antimicrobial, 
antitubercular and antiproliferative activities of 
quercetin isolated from the marine Streptomyces 
fradiae. Bangladesh Journal of Pharmacology, v. 
12, n. 3, p. 333-334. 
[19] Schleifer, K. H.; Kloos, W. E. (1975). Isolation and 
characterization of staphylococci from human skin. 
International Journal of Systematic Bacteriology , v. 
25, n. 1, p. 50-61. 
[20] Sousa, V. S.; Silva, A. P.; Sorenson, L.; Paschoal, R. 
P.; Rabello, R. F.; Campana, E. H. et al (2017). 
Staphylococcus saprophyticus recovered from 
humans, food, and recreational waters in Rio de 
Janeiro, Brazil. International Journal of 
Microbiology, v. 2017, p. 1-12. 
[21] Clinical and Laboratory Standards Institute (CLSI). 
Performance Standards for Antimicrobial 
Susceptibility Testing. 27th Edition (M100-S27). 
Wayne, PA, 2016. 
[22] Freeman, D. J.; Falkiner, F. R.; Keane C. T. (1989). 
New method for detecting slime production by 
coagulase negative staphylococci. Journal of 
Clinical Pathology, v. 42, n. 8, p. 872-874. 
[23] Stepanović, S.; Vuković, D.; Dakić, I.; Savić, B.; 
Švabić-Vlahović, M. A. (2000). A modified 
microtiter-plate test for quantification of 
staphylococcal biofilm formation. Journal of 
Microbiological Methods, v. 40, n. 2, p. 175–179. 
[24] Das, P.; Yang, X-P.; Ma, L.Z. (2014). Analysis of 
biosurfactants from industrially viable Pseudomonas 
strain isolated from crude oil suggests how 
rhamnolipids congeners affect emulsification 
property and antimicrobial activity. Frontiers in 
Microbiology, v. 5, n. 3, p. 1-8. 
[25] Sina, H.; Semassa, J. A.; Dougnon, V. T.; Adjilé, A. 
A.; Baba-Moussa, F.; Bankolé, H. S.; Baba-Moussa, 
L. (2018). Antibiotics resistance profile of 
staphylococci isolated from urogenital infections and 
toxins production of Staphylococcus aureus strains. 
Annals of Medical and Health Sciences Research , v. 
8, p. 29-34.  
[26] Howden, B. P.; Davies, J. K.; Johnson, P. D. R.; 
Stinear, T. P.; Grayson, M. L. (2010). Reduced 
vancomycin susceptibility in Staphylococcus aureus, 
including vancomycin-intermediate and 
heterogeneous vancomycin-intermediate strains: 
resistance mechanisms, laboratory detection and 
clinical implications. Clinical Microbiology 
Reviews, v. 23, n. 1, p. 99-139. 
[27] McGuinness, W. A.; Malachowa, N.; DeLeo, F. R. 
(2017). Vancomycin resistance in Staphylococcus 
aureus. Yale Journal of Biology and Medicine, v. 90, 
n. 2, p. 269-281. 
[28] Almeida, M. I.; Bedendo, J.; Cavasin, E. D.; 
Tognim, M. C. B. (2007). Prevalência e perfil de 
sensibilidade de amostras de Staphylococcus aureus 
isoladas de casos clínicos de infecções hospitalares. 
Revista Eletrônica de Enfermagem, v. 9, n. 2, p. 
489-495. 
[29] Moreira, A. C. M. G.; Santos, R. R.; Bedendo J. 
(2013). Prevalência e perfil de sensibilidade de 
Staphylococcus aureus isolados em pacientes e 
equipe de enfermagem. Ciência, Cuidado e Saúde, 
v. 12, n. 3, p. 572-579. 
[30] Tiwari, H. K.; Sen, M. R. (2006). Emergence of 
vancomycin resistant Staphylococcus aureus 
(VRSA) from a tertiary care hospital from northern 
part of India. BMC Infectious Diseases, v. 6, n. 156, 
p. 1-6. 
[31] Hannan, A.; Akhtar, R. W.; Saleem, S.; Qaisar, A.; 
Jahan, S. (2018). Frequency of vancomycin resistant 
Staphylococcus aureus among clinical isolates of 
MRSA collected from tertiary care hospitals of 
lahore, Pakistan. Pakistan Armed Forces Medical 
Journal, v. 68, n. 3, p. 580-584.   
[32] Hassan, A.; Usman, J.; Kaleem, F.; Omair, M.; 
Khalid, A.; Iqbal, M. (2011). Evaluation of different 
detection methods of biofilm formation in the 
clinical isolates. The Brazilian Journal of Infectious 
Diseases, v. 15, n. 4, p. 305-311. 
[33] Shrestha, L.; Bhattarai, N. R.; Khanal, B. (2018). 
Comparative evaluation of methods for the detection 
of biofilm formation in coagulase-negative 
staphylococci and correlation with antibiogram. 
Infection and Drug Resistance, v. 2018, n. 11, p. 
607-613. 
[34] RESEARCH ON MICROBIAL BIOFILMS (PA-03-
047). NIH, National Heart, Lung, and Blood 
Institute. 2002-12-20. 
[35] Chakraborty, S.; Dutta, T.K.; Das, M. A.; Ghosh, S. 
(2018). Impact of bacterial biofilm in veterinary 
medicine: An Overview. International Journal of 
Current Microbiology and Applied Sciences, v. 7, n. 
4, p. 3228-3239.  
[36] Simonetti, E.; Ethur, M. E.; Castro, L. C.; 
Kauffmann, C.; Giacomin, A. C.; Ledur, A. et al. 
(2016). Avaliação da atividade antimicrobiana de 
extratos de Eugenia anomala e Psidium salutare 
(Myrtaceae) frente à Escherichia coli e Listeria 
monocytogenes. Revista Brasileira de Plantas 
Medicinais, v. 18, n. 1, p. 9-18. 
[37] Rauha, J-P.; Remes, S.; Heinonen, M.; Hopia, A.; 
Kähkönen, M.; Kujala, T. et al. (2000). 
Antimicrobial effects of Finnish plant extracts 
 International Journal of Environment, Agriculture and Biotechnology (IJEAB)                             Vol-3, Issue-5, Sept-Oct- 2018 
http://dx.doi.org/10.22161/ijeab/3.5.50                                                                                                                      ISSN: 2456-1878 
www.ijeab.com                                                                                                                                                                           Page | 1958  
containing flavonoids and other phenolic 
compounds. International Journal of Food 
Microbiology, v. 56, n. 1, p. 3–12. 
[38] Nitiema, L. W.; Savadogo, A.; Simpore, J.; Dianou, 
D.; Traore, A. S. (2012). In vitro antimicrobial 
activity of some phenolic compounds (coumarin and 
quercetin) against gastroenteritis bacterial strains. 
International Journal of Microbiological Research , 
v. 3, p. 183-187. 
[39] Hirai, I.; Okuno, M.; Katsuma, R.; Arita, N.; 
Tachibana, M.; Yamamoto, Y. (2010). 
Characterisation of anti-Staphylococcus aureus 
activity of quercetin. International Journal of Food 
Science & Technology, v. 45, n. 6, p. 1250-1254. 
[40] Lee, J-H.; Park, J-H.; Cho, H. S.; Joo, S. W.; Cho, 
M. H.; Lee, J. (2013). Anti-biofilm activities of 
quercetin and tannic acid against Staphylococcus 
aureus. Biofouling, v. 29, n. 5, p. 491-499.  
[41] Yang B.; Lei, Z.; Zhao, Y.; Ahmed, S.; Wang, C.; 
Zhang, S. (2017). Combination susceptibility testing 
of common antimicrobials in vitro and the effects of 
sub-MIC of antimicrobials on Staphylococcus 
aureus biofilm formation. Frontiers in 
Microbiology, v. 8, n. 2125, p. 1-14. 
